Literature DB >> 11568074

Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis.

K Suzuki1, B Murtuza, R T Smolenski, I A Sammut, N Suzuki, Y Kaneda, M H Yacoub.   

Abstract

BACKGROUND: Interleukin-1 (IL-1) plays a role in mediating acute inflammation during ischemia-reperfusion (I/R) injury in the heart, which leads to both necrosis and apoptosis of cardiomyocytes. IL-1 receptor antagonist (IL-1ra) is known to inhibit the effects of IL-1alpha and IL-1beta, resulting in attenuated inflammatory injury, and to protect cells from IL-1beta-induced apoptosis in vitro. We hypothesized that IL-1ra overexpression would provide cardioprotection by reducing inflammation-mediated myocardial damage including apoptosis after I/R injury in vivo. METHODS AND
RESULTS: Rat hearts were transfected with human secreted-type IL-1ra gene by intracoronary infusion of Hemagglutinating Virus of Japan liposome and were heterotopically transplanted. IL-1ra overexpression in these hearts was confirmed by enzyme immunoassay and immunohistochemistry. Myocardial tolerance of the transplanted heart was evaluated with the use of a novel system in which the heart, existing within the recipient's abdomen, was given 30 minutes of ischemia by left coronary artery occlusion and 24 hours of reperfusion. Consequently, infarct size was decreased in IL-1ra-transfected hearts compared with control-transfected ones (26.9+/-3.2% versus 46.2+/-3.0%, P=0.001), corresponding to lower myocardial myeloperoxidase activity (2.20+/-0.69 versus 6.82+/-1.19 U/g wet wt, P<0.001) and decreased neutrophil infiltration in histological study. Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling and DNA-laddering studies demonstrated that cardiomyocyte apoptosis was attenuated in IL-1ra-transfected hearts (21.4+/-3.3 versus 41.4+/-3.4%, P=0.002), correlating with reduced post I/R upregulation of Bax, Bak, and caspase-3.
CONCLUSIONS: IL-1ra introduced by gene transfection protected myocardium from I/R injury by attenuating the inflammatory response, which was associated with decreased apoptosis. This suggests a potentially important role of IL-1/IL-1ra in myocardial I/R injury and the value of IL-1ra-gene therapy for myocardial preservation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568074     DOI: 10.1161/hc37t1.094871

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  60 in total

Review 1.  The role of the inflammasome in nonmyeloid cells.

Authors:  Amir S Yazdi; Stefan K Drexler; Jürg Tschopp
Journal:  J Clin Immunol       Date:  2010-06-27       Impact factor: 8.317

Review 2.  Immune response to stem cells and strategies to induce tolerance.

Authors:  Puspa Batten; Nadia A Rosenthal; Magdi H Yacoub
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-08-29       Impact factor: 6.237

Review 3.  Systemic inflammation in heart failure--the whys and wherefores.

Authors:  Arne Yndestad; Jan Kristian Damås; Erik Oie; Thor Ueland; Lars Gullestad; Pål Aukrust
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

Review 4.  Sensing damage by the NLRP3 inflammasome.

Authors:  Jaklien C Leemans; Suzanne L Cassel; Fayyaz S Sutterwala
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

Review 5.  Micromanaging cardiac regeneration: Targeted delivery of microRNAs for cardiac repair and regeneration.

Authors:  Jan Aam Kamps; Guido Krenning
Journal:  World J Cardiol       Date:  2016-02-26

6.  Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study.

Authors:  Michaela R Anderson; Jayaram K Udupa; Ethan Edwin; Joshua M Diamond; Jonathan P Singer; Jasleen Kukreja; Steven R Hays; John R Greenland; Anthony Ferrante; Matthew Lippel; Tatiana Blue; Amika McBurnie; Michelle Oyster; Laurel Kalman; Melanie Rushefski; Caiyun Wu; Gargi Pednekar; Wen Liu; Selim Arcasoy; Joshua Sonett; Frank D'Ovidio; Matthew Bacchetta; John D Newell; Drew Torigian; Edward Cantu; Donna L Farber; Jon T Giles; Yubing Tong; Scott Palmer; Lorraine B Ware; Wayne W Hancock; Jason D Christie; David J Lederer
Journal:  J Heart Lung Transplant       Date:  2019-08-10       Impact factor: 10.247

7.  Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice.

Authors:  Prasanna Krishnamurthy; Erin Lambers; Suresh Verma; Tina Thorne; Gangjian Qin; Douglas W Losordo; Raj Kishore
Journal:  FASEB J       Date:  2010-03-10       Impact factor: 5.191

8.  Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

Authors:  Antonio Abbate; Benjamin Wallace Van Tassell; Giuseppe Biondi-Zoccai; Michael Christopher Kontos; John Dallas Grizzard; Debra Whittaker Spillman; Claudia Oddi; Charlotte Susan Roberts; Ryan David Melchior; George Herman Mueller; Nayef Antar Abouzaki; Lenore Rosemary Rengel; Amit Varma; Michael Lucas Gambill; Raquel Appa Falcao; Norbert Felix Voelkel; Charles Anthony Dinarello; George Wayne Vetrovec
Journal:  Am J Cardiol       Date:  2013-02-27       Impact factor: 2.778

9.  Myocardial uptake of 99mTc-annexin-V and 111In-antimyosin-antibodies after ischemia-reperfusion in rats.

Authors:  Laure Sarda-Mantel; Florence Hervatin; Jean-Baptiste Michel; Liliane Louedec; Geneviève Martet; François Rouzet; Rachida Lebtahi; Pascal Merlet; Ban-An Khaw; Dominique Le Guludec
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-05       Impact factor: 9.236

10.  IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR.

Authors:  Prasanna Krishnamurthy; Johnson Rajasingh; Erin Lambers; Gangjian Qin; Douglas W Losordo; Raj Kishore
Journal:  Circ Res       Date:  2008-12-18       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.